AHA 2024. [7]. Tess Calcagno, et al. Impact of SGLT2 Inhibitors on Cardiovascular Outcomes Following Acute Myocardial Infarction with Heart Failure with Preserved Ejection Fraction: A Propensity-Matched Registry Study. AHA 2024. [8]. Bruce Neal, et al. Canagliflozin and Cardiovascular and Renal ...
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i)Heart failure (HF)Heart failure with preserved ejection fraction (HFpEF)Heart failure with reduced ejection fraction (HFrEF)SGLT-2i have emerged as a novel treatment for both prevention of HF and reduction of cardiovascular morbidity and mortality ...
SGLT-2 inhibitorsType 2 diabetescardiovascular outcomeheart failure hospitalizationHeart failure (HF) in type 2 diabetes mellitus (T2DM) poses a significant increase in mortality. Until recently, anti-diabetic drugs have not been shown to reduce hospitalization due to heart failure (hHF). While ...
Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in patients with heart failure and preserved ejection fraction (HFpEF). In the midst of the Coronavirus Disease 2019 pandemi...
The Research Into the Effect of SGLT2 Inhibition on Left Ventricular Remodeling in Patients With Heart Failure and Diabetes Mellitus (REFORM) trial was the first to try to determine the mechanistic effect of SGLT2-inhibitors specifically in the HF population. At 1 year, no significant difference ...
[2]Stephanie Viguers. Study shows early benefits of SGLT2 inhibitors in patients with heart failure[EB/OL]. [2022-4-11].https://www.healio.com/news/primary-care/20220411/study-shows-early-benefits-of-sglt2-inhibitors-in-patients-with-heart-failure....
Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multic...
首都医科大学附属北京佑安医院陈煜教授,高原医生、清华大学附属北京清华长庚医院魏来教授和信诺医讯Dorothy Zhang、侯冰教授合作在Journal of Clinical and Translational Hepatology (JCTH)2021年第6期以Letter to the Editor形式发表独立观点性文章...
[4]O'Meara E, McDonald M,Chan M,et al.CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors,ARNl in HFpEF, and Tafamidis in Amyloidosis[]]Can J Cardiol,2020,36(2):159-169.
2.Stephanie Viguers. Study shows early benefits of SGLT2 inhibitors in patients with heart failure. Healio. April 11, 2022.